Research programme: stem cell therapies - Cytovis
Alternative Names: CytoCor; CytoRetLatest Information Update: 02 Nov 2017
At a glance
- Originator International Stem Cell Corporation
- Developer Cytovis; University of California at Irvine
- Class Eye disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Corneal disorders; Retinal disorders
Most Recent Events
- 31 Oct 2017 International Stem Cell Corporation receives patent allowance for methods for generating HLA homozygous parthenogenetic human stem cell lines in Australia
- 16 Jul 2016 No recent reports of development identified for preclinical development in Corneal-disorders in USA (Intraocular, Implant)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Intraocular, Implant)